TG Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on TG Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date TG Therapeutics Inc Strategy Report
- Understand TG Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases. The company’s approved products in the US include Briumvi for the treatment of relapsing forms of multiple sclerosis. The pipeline products of the company include Ublituximab, TG-1701, TG-1801, and Azer-Cel for the treatment of B-cell cancers and other diseases. The company also evaluates products and technologies for in-licensing, partnership, acquisition, and investment. The company has operations in the US and Australia. TG Therapeutics is headquartered in New York City, New York, the US.
TG Therapeutics Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Briumvi (ublituximab- xiiy): Relapsing Forms of Multiple Sclerosis | - |
Pipeline | Briumvi |
Ublituximab: Relapsing Forms of Multiple Sclerosis (RMS) | TG Patient Support |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | New Products/Services | In February, the company along with Neuraxpharm Group launched Briumvi (ublituximab-xiiy) in Europe, for the treatment of adults patients with relapsing forms of multiple sclerosis (RMS). |
2024 | Contracts/Agreements | In January, the company entered into an agreement with Precision BioSciences Inc to acquire a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel). |
2023 | Contracts/Agreements | In August, the company and Neuraxpharm Group entered into an agreement for the commercialization of BRIUMVI (ublituximab) in Europe. |
Competitor Comparison
Key Parameters | TG Therapeutics Inc | Acorda Therapeutics Inc | Infinity Pharmaceuticals Inc | Cyclacel Pharmaceuticals Inc | Hoffmann-La Roche Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Morrisville | Pearl River | Cambridge | Berkeley Heights | Essex County |
State/Province | North Carolina | New York | Massachusetts | New Jersey | New Jersey |
No. of Employees | 264 | 102 | 30 | 12 | - |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Michael S. Weiss | Chief Executive Officer; President; Chairman | Executive Board | 2011 | - |
Sean A. Power | Chief Financial Officer | Senior Management | 2011 | - |
Adam Waldman | Chief Commercial Officer | Senior Management | 2018 | - |
Daniel Hume | Director | Non Executive Board | 2015 | - |
Kenneth Hoberman | Director | Non Executive Board | 2014 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer